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ABSTRACT five members who agreed to regular follow-up. 
Inherited pheochromocytomas are often part of familial syn- 
dromes, especially multiple endocrine neoplasia type 2 (MEN 2), ret- 
inal cerebellar hemangioblastomatosis [van Hippel-Lindau (vHL) dis- 
ease] or neurofibromatosis type 1. It is not clear whether isolated 
familial pheochromocytoma exists as a separate clinical entity. 
In a family with pheochromocytomas in three generations and with 
at least seven affected members, we investigated by clinical and genetic 
analyses the presence or absence of associated conditions. The clinical 
investigations included ophthalmological and radiological studies for 
von Hippel-Lindau disease (magnetic resonance imaging of the brain, 
computed tomography of the abdomen, and direct ophthalmoscopy after 
mydriasis) and annual calcitonin stimulation tests for C cell disease in 
Besides the pheochromocytomas (so far, these have been multiple in 
five of seven individuals) no definite second associated condition was 
found. Genetic analysis did not identify any MEN 2-specific RET pro- 
tooncogene point mutations (which are present in 97% of MEN 2a fam- 
ilies). However, despite the complete absence of other clinical manifes- 
tations of the vHL disease (besides pheochromocytomas), a previously 
undescribed germline m&sense mutation in the vHL tumor suppressor 
gene was found (C775G transversion with a predicted substitution of a 
leucine by a valine at codon 259 in the putative vHL protein). 
We conclude that in this family the sole occurrence of pheochro- 
mocytoma is a variant of vHL disease. (J Clin Endocrinol Metab 81: 
1035-1037, 1996) 
A PPROXIMATELY 10% of pheochromocytomas are be- lieved to be inherited (1). Most of them are part of 
familial syndromes with an autosomal dominant mode of 
inheritance and other associated conditions, especially mul- 
tiple endocrine neoplasia type 2 (MEN 21, retinal cerebellar 
hemangioblastomatosis [von Hippel-Lindau (vHL) disease] 
and, rarely, neurofibromatosis type 1. A recent study de- 
scribed the detection of associated familial disease in as many 
as 19 of 82 patients (23%) presenting with pheochromocy- 
toma (3 families with MEN 2 and 16 with vHL disease), 
suggesting an even higher prevalence and clinical impor- 
tance of familial pheochromocytoma (2). 
As all familial pheochromocytoma in the latter study were 
associated with MEN 2 or vHL disease, the question arises 
of whether familial pheochromocytoma without other famil- 
ial conditions exists as an entity. Previously described fam- 
ilies (3,4) have not included extensive work-ups (including 
a calcitonin stimulation test) to rule out the existence of these 
associated disorders, especially of MEN 2. 
Since 1988 we have followed a family’ with pheochromo- 
cytomas in three generations and with at least seven affected 
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i Before the possibility of vHL genetic analysis, this family was er- 
roneously described as a MEN 2 family (by 2, family 3). 
members. For reasons stated below, this family was looked 
upon as a MEN 2 family. Because of the clinical presentation 
with only adrenal disease, and as total thyroidectomy in the 
index patient disclosed only a focal presence of C cells but no 
medullary thyroid carcinoma, we were not convinced of this 
classification. With the recent availability of genetic diagnosis, 
we were able to disprove the diagnosis of MEN 2, which has 
clinical consequences for the family. Furthermore, a new mu- 
tation in the vHL disease suppressor gene found in this family 
demonstrates that the clinical diagnosis of a familial pheochro- 
mocytoma-only variant might be a form of the vHL disease. 
Patients 
Subjects and Methods 
Since 1988 we have followed a family with pheochromocytomas (the 
pedigree is given in Fig. 1). The minimal annual examination included 
a medical history; physical examination; measurement of urinary ex- 
cretion of vanilmandelic acid, total metanephrines, norepinephrine, and 
epinephrine; and measurement of serum total calcium concentration 
and basal and stimulated calcitonin concentrations. With the exceptions 
stated below, morphological studies were performed in all family mem- 
bers with suspected or proven pheochromocytomas. This included mag- 
netic resonance imaging of the brain, computed tomography of the 
abdomen, [‘3’I]metaiodobenzylguanidine scintigraphy, direct ophthal- 
moscopy after mydriasis, and ultrasonography of the testes. These stud- 
ies were performed using standard techniques and with special attention 
to the manifestations of MEN 2 and vHL disease. All studies were 
conducted after informed consent had been obtained. 
Biochemical analyses 
In 24-h urine collections, epinephrine, norepinephrine, metaneph- 
rine, normetanephrine, and vanilmandelic acid were measured, as de- 
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FIQ. 1. Pedigree of the investigated family. Circles denote females; 
squares denote males. The right half of each symbol indicates the 
presence (solid area) or absence (open area) of left-sided pheochro- 
mocytoma (and vice uersa); the middle portion denotes extraadrenal 
pheochromocytoma. 
scribed previously (5). Calcitonin stimulation tests were performed by 
combined stimulation with iv calcium and pentagastrin (6). Measure- 
ment of calcitonin was made with an immunoradiometric assay from 
Medgenix (Fleuris, Belgium). From 1988-1989, the test was considered 
positive if the stimulated value exceeded 120 pg/mL. In 1990, we es- 
tablished new reference values (7), and stimulated calcitonin values up 
to 400 pg/mL were considered normal. 
Genetic analyses 
MEN 2. Genomic DNA was isolated from peripheral leukocytes using 
an automated DNA extractor, as previously described (8). One hundred 
nanograms of DNA were I’CR amplified for exons 10 (primer CRT 19s 
and CRT 2C or CRT 19s and CRT 19E9), 11 (CRT 19s and 2C or CRT 19B 
and 2C), and 16 (CRT 5G and CRT 5H or F RET 16 and R RET 16). 
Twenty-five-microliter samples contained 10 mmol/L Tris-HCl (pH 8.3), 
50 mmol/L KCl, 0.75 mmol/L MgCI,, 0.01% gelatin, 200 pmol/L deoxy- 
NTPs, and 1 U Taq polymerase with 1 pmol/L each of the appropriate 
PCR primers. DNA was amplified for 40 cycles of 1 min each at 95,55, 
and 72 C. PCR products were separated by electrophoresis on 2% low 
melting temperature agarose gels and eluted using the Magic PCR Prep 
system (Promega, Southampton, UK). Purified amplification products 
were sequenced using the delta Taq cycle sequencing kit (U.S. Biochem- 
ical Corp., Cleveland, OH). The sequences were resolved on 5% dena- 
turing polyacrylamide gels. 
vHL disease. Screening for vHL gene mutations was performed as described 
previously. Briefly, the cloned coding sequence of the vHL gene was am- 
plified from genomic DNA using six sets of primer sequences, and each 
fragment was examined for point mutations by single strand conforma- 
tional polymorphism analysis (9). The nucleotide sequence of PCR products 
showing band shifts on single strand conformational polymorphism anal- 
ysis was determined by direct sequencing with nested primers, using a 
commercially available cycle sequencing kit (Life Technologies, Grand Is- 
land, NY) according to the manufacturer’s guidelines. 
Patients 
Results 
With respect to the pedigree shown in Fig. 1, patient I,1 
refused clinical investigations, with the exception of an ul- 
trasonography that demonstrated bilateral adrenal tumors 
but normal renal and thyroid morphology. She also agreed 
to determination of the basal calcitonin level, which was 
normal, and a genetic analysis. 
Patient II,1 died in childbirth with the symptoms and signs 
of a hypertensive crisis. Whole body autopsy showed a left 
adrenal and an extraadrenal pheochromocytoma, but no 
other features of MEN 2 or vHL disease. The child died 1 day 
after birth from a cerebral hemorrhage. 
Patient II,3 claimed that after performing an ultrasonog- 
raphy her family doctor had told her that she was not affected 
by the family disease. She agreed only to the genetic analysis. 
All other patients (1,2; 11,2; 11,4; 11,5; and 111,l) were screened 
for MEN 2 and vHL disease. With one exception all results 
were normal. In patient 11,2, two calcitonin stimulation tests 
were performed, which demonstrated increases from a nor- 
mal basal value (37 and 39 pg/mL) to 141 and 295 pg/mL. 
At that time our upper normal value for calcitonin during the 
stimulation test was 120 pg/mL, and we considered this 
increase to be indicative of C cell hyperplasia. After extensive 
discussion with the patient, thyroidectomy was performed 
despite normal ultrasonography of the thyroid. Only a focal 
presence of C cells, but no medullary thyroid carcinoma, was 
found. Postoperatively, calcitonin was no longer detectable 
(<lo pg/mL basally and after stimulation). 
Genetic analyses 
We were not able to identify any MEN 2A-specific RET 
point mutations in genomic DNA of the family members 
tested at codons 609,611,618,620, and 634 in exons 10 and 
11, respectively. Furthermore, no mutations were found in 
exon 16 (codon 918). 
Examination of the vHL gene identified a C to G trans- 
version at nucleotide 775 of the published coding sequence 
(10). This sequence change was predicted to cause a substi- 
tution of a leucine by a valine at codon 259 in the putative 
vHL protein. The C775G change segregated with the disease 
and has not been detected in analysis of more than 400 
normal vHL alleles. 
Discussion 
We describe a family suffering from familial pheochromo- 
cytoma with seven affected subjects in three generations. In the 
absence of cutaneous manifestations and, therefore, exclusion 
of neurofibromatosis type 1, we had to differentiate among the 
diagnoses of MEN 2, retinal cerebellar hemangioblastomatosis, 
and isolated familial pheochromocytoma. 
The diagnosis of MEN 2 appeared unlikely because none of 
the affected family members (at 14,20,29,42,45,59, and 71 yr 
of age) suffered from overt thyroid disease, and an adequately 
and repeatedly performed screening for medullary thyroid car- 
cinoma gave normal results in 4 of 5 patients. In 25 patients, 
members of 5 MEN 2 families, we have found no patient with 
a pheochromocytoma or primary hyperparathyroidism with- 
out C cell disease (unpublished data). However, Gage1 et al. (11) 
described adrenal disease preceding by 5 and 8 yr the detection 
of C cell abnormalities in 2 of 19 MEN 2 patients with pheo- 
chromocytoma. Thus, the detection of adrenal disease as the 
first manifestation in MEN 2 patients is occasionally possible; 
however, the absence of thyroid disease 24 yr (patient 11,4) and 
12 yr (patient 11,5) after detecting pheochromocytoma would 
have been unprecedented. 
One patient (II,21 had a calcitonin stimulation test that was 
considered abnormal. Consequently, thyroidectomy was per- 
formed. At that time, we used an upper normal limit for cal- 
citonin during the stimulation test of 120 pg/mL. Subsequently, 
based on tests in 20 healthy volunteers, we established an upper 
normal limit for stimulated calcitonin of 400 pg/mL (7). The 
histological evaluation in this patient showed only focal C cell 
hyperplasia, but no medullary thyroid carcinoma. Focal C cell 
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hyperplasia can represent a normal finding in the thyroids of 
children less than 6 yr of age and in elderly patients (12). Re- 
cently, positive stimulation tests and C cell hyperplasia in the 
operated thyroid were described as a normal finding in unaf- 
fected members of MEN 2 families (13). Thus, we now judge the 
calcitonin stimulation test performed preoperatively on patient 
II,2 as normal and the histological findings as not proven for 
MEN 2-associated C cell disease. 
Mutations in the RET protooncogene were identified as the 
genetic defect in MEN 2 (14, 15). Based on this experience, 
genetic analysis of the family was carried out. RET protoonco- 
gene mutations in exons 10 and 11 are present in 97% of MEN 
2A families and in 86% of the patients with familial medullary 
thyroid carcinoma (16). In almost all MEN 2B patients tested 
recently, mutations in exon 16 were detectable (17). 
We were not able to detect any MEN 2-specific RET pro- 
tooncogene mutations in exons 10, 11, and 16 and concluded 
that the diagnosis of MEN 2 was extremely unlikely. There- 
fore, calcitonin stimulation tests were no longer needed in the 
care of this family. 
At about the time of the discovery of the MEN 2 gene, 
rearrangements in a gene named vHL disease tumor sup- 
pressor gene were identified as the causal defect for vHL 
disease (10). Therefore, a search for a defect in this gene in 
the described family was performed. Despite the complete 
absence of other clinical manifestations, a mutation in the 
vHL tumor suppressor gene was found. 
The positive finding of a mutation in this gene obviates the 
need for further testing in the RET protooncogene, as addi- 
tional mutations in 3% of MEN 2a families were found that 
do not harbor one of the common mutations in codons 609, 
611,618,620, and 634 (these showed only the wild-type allele 
in this family) (18). 
The presence of pheochromocytoma in 20% of vHL families 
is often used to classify the disease into two types; families 
without pheochromocytoma are described as vHL type 1, and 
those with pheochromocytoma as vHL type 2 (19-21). Inter- 
esting correlations between this phenotype expression and the 
types of mutations in the vHL disease tumor suppressor gene 
have been reported (9, 21). In short, missense mutations (in 
contrast to deletions, insertions, and nonsense mutations) are 
found significantly more often in families with vHL type 2. 
The family described in this manuscript is the first reported 
family with a mutation in the vHL disease tumor suppressor 
gene, but with pheochromocytoma as the only manifestation of 
vHL disease (i.e. without angiomas, hemangioblastomas, and 
renal cell carcinomas). Therefore, the family cannot be assigned 
to one of the two above-mentioned types of vHL disease. The 
C775G mutation detected in this family has not been described 
previously, but it is interesting to note that it is also a missense 
mutation. Furthermore, the mutation identified is at the very 
3’-end of the vHL disease tumor suppressor gene, and the 
substitution of leucine by valine is supposed to cause little 
conformational change in the putative vHL protein. The ab- 
sence of other vHL manifestations in all seven members of the 
family is unlikely to be coincidental given the prevalence and 
mean age at onset of the other clinical features of the disease 
(22). Therefore, the association of this particular mutation with 
such a pheochromocytoma-only variant of vHL disease might 
contribute to an understanding of the genetic mechanisms of 
vHL disease. 
In conclusion, we have shown that in this family, the sole 
occurrence of pheochromocytoma is a minor variant of vHL 
disease. To emphasize both the relationship to and the dis- 
tinction from the full blown syndrome, we propose that this 
pheochromocytoma-only variant be called vHL type 3. 
Note added in proof: 
Since the writing of the manuscript, the numbering of the vHL coding 
sequence has been changed: codon 259 is now counted as codon 188 (Il- 
iopoulos 0, Kibel A, Gray S, Kaelin WG. 1995 Tumor suppression by the 
human von Hippel-Lindau gene product. Nature Medicine 1: 822-826). 
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